What's new? Log in Free sign up

HUTCHMED (HCM)

Company Profile

Company profile

Ticker

HCM, HMDCF

Exchange

Website

www.hutch-med.com

CEO

Dr. Wei-Guo Su B.Sc., Ph.D.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

Hutchison China MediTech Ltd

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

HCM stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Current report (foreign)

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

Current report (foreign)

Vesting of awards under the Long Term Incentive Plan

Current report (foreign)

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Capital International Investors

Capital International Investors

GENERAL ATLANTIC LLC

CK Hutchison Holdings Ltd

CK Hutchison Holdings Ltd

Capital International Investors

CK Hutchison Holdings Ltd

CK Hutchison Holdings Ltd

Financial summary

Financial statements Chart HCM financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from HUTCHMED earnings reports.

Institutional ownership, Q2 2024

HCM institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	65	63	+3.2%
Opened positions	17	20	-15.0%
Closed positions	15	11	+36.4%
Increased positions	15	18	-16.7%
Reduced positions	20	16	+25.0%

13F shares	Current	Prev Q	Change
Total value	139.30 bn	193.88 bn	-28.2%
Total shares	341.08 mm	344.70 mm	-1.0%
Total puts	2.40 k	0.00	NEW
Total calls	3.80 k	0.00	NEW
Total put/call ratio	0.6	–	–

Largest owners	Shares	Value	Change
CK Hutchison	332.50 mm	$0.00	0.0%
Schroder Investment Management	3.02 mm	$51.78 bn	-21.4%
Allianz Asset Management GmbH	1.50 mm	$25.71 bn	NEW
BLVGF Bellevue	1.15 mm	$19.67 bn	-0.5%
Acadian Asset Management	389.12 k	$6.65 mm	-20.1%
Millennium Management	357.63 k	$6.12 bn	NEW
STT State Street	346.45 k	$5.93 bn	+0.8%
AAGIY AIA Group Limited	315.44 k	$5.40 bn	-15.9%
BNP Paribas Arbitrage	191.15 k	$3.27 bn	+345.3%
Amundi	173.89 k	$3.05 bn	-31.0%

Largest transactions	Shares	Bought/sold	Change
General Atlantic	0.00	-4.00 mm	EXIT
Allianz Asset Management GmbH	1.50 mm	+1.50 mm	NEW
Schroder Investment Management	3.02 mm	-825.46 k	-21.4%
Millennium Management	357.63 k	+357.63 k	NEW
Jane Street	13.63 k	-261.60 k	-95.0%
HBCYF HSBC	0.00	-183.77 k	EXIT
BNP Paribas Arbitrage	191.15 k	+148.23 k	+345.3%
M&G	134.90 k	-127.31 k	-48.6%
FIL	0.00	-113.63 k	EXIT
Platinum Investment Management	0.00	-110.37 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance

US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe —— Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for

Reported Earlier, HUTCHMED's ORPATHYS and TAGRISSO Combo Gains Therapy Designation in China for Advanced Lung Cancer

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China's National Medical Products Administration ("NMPA") has granted Breakthrough Therapy

Hutchmed And Innovent Biologics Announce That Elunate (Fruquintinib) And Tyvyt (Sintilimab) Combination Has Received Conditional Approval In China For Advanced Endometrial Cancer With Mismatch Repair Proficient Tumors That Have Failed Prior Systemic Therapy And Are Not Candidates For Curative Surgery Or Radiation

The conditional approval by the NMPA was supported by registration stage data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase II study investigating fruquintinib in

Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List

Reported Earlier, HUTCHMED Secures Milestone Payment As Takeda Rolls Out FRUZAQLA In Japanese Market

Press releases

From Benzinga Pro

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China's National

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.